Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis by means of sublingual allergen-specific immunotherapy
- Authors: Lemeshko V.A.1, Ratushnyak S.S.2, Gorkavenko F.V.2, Nazarova E.V.3, Ilina N.I.3, Omelyanovskiy V.V.1,2,4
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- The Center for Healthcare Quality Assessment and Control
- National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia
- Federal state budgetary institution Scientific and research financial institute
- Issue: Vol 18, No 4 (2021)
- Pages: 5-17
- Section: Original studies
- URL: https://journals.rcsi.science/raj/article/view/121583
- DOI: https://doi.org/10.36691/RJA1497
- ID: 121583
Cite item
Abstract
BACKGROUND: Allergic rhinitis is the most common chronic allergic disease worldwide, and bronchial asthma (BA) is one of the most severe complications of allergic rhinitis. Clinical studies reported that sublingual allergen-specific immunotherapy can reduce the incidence of bronchial asthma in children and adults. However, allergen-specific immunotherapy is rather expensive and is not reimbursed by the state, which transfers the cost of this therapy to patients.
AIMS: To evaluate the cost-effectiveness of allergen-specific immunotherapy in children and adults with allergic rhinitis and/or allergic rhinoconjunctivitis
MATERIALS AND METHODS: The study hypothesized based on study results by Devillier P. et al. in 2019, to which the incidence of asthma was 13.7% and 17.0% in the sublingual allergen-specific immunotherapy + symptomatic therapy and the symptomatic therapy group, respectively (odds ratio: 0.776, 95% confidence interval [0.622; 0.968]). Pharmacoeconomic study based on decision tree model. Costs taken into account are the following: allergen-specific immunotherapy, symptomatic therapy, diagnostics, and routine follow-up visits due to bronchial asthma, outpatient bronchial asthma drug therapy, and hospitalization due to bronchial asthma. The modeling horizon was 5 years, including 2 years of allergen-specific immunotherapy therapy and 3 years of follow-up.
RESULTS: The cost per patient when using allergen-specific immunotherapy in combination with symptomatic therapy was 166,711.93 rubles, whereas with symptomatic therapy was 101,700.35 rubles. The cost-effectiveness ratio for allergen-specific immunotherapy in combination with symptomatic therapy was 193,177.20 rubles per 1 prevented case of asthma, whereas 122,530.55 rubles for symptomatic therapy for 1 prevented case of bronchial asthma. Thus, the cost of 1 averted bronchial asthma case when using allergen-specific immunotherapy in combination with symptomatic therapy is 57.7% higher than with symptomatic therapy. The cost-benefit analysis result revealed that the incremental cost-utility ratio for an additional year of life adjusted for its quality when performing sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared with symptomatic therapy alone in children and adults was 567,365.48 rubles, which is less than the calculated willingness to pay threshold (RUB 2,248,898.50).
CONCLUSIONS: The comparison results of the cost of 1 added quality adjusted life years and willingness to pay threshold concluded that sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared to symptomatic therapy alone is potentially cost-effective in children and adults with allergic rhinitis.
Full Text
##article.viewOnOriginalSite##About the authors
Valeriya A. Lemeshko
Russian Medical Academy of Continuous Professional Education
Email: lera.lemeschko@yandex.ru
ORCID iD: 0000-0002-7452-6940
SPIN-code: 6391-6847
Russian Federation, Khohlovsky lane 10, bldg. 5, Moscow 109028
Svetlana S. Ratushnyak
The Center for Healthcare Quality Assessment and Control
Email: svetlanarshk@gmail.com
ORCID iD: 0000-0001-7967-5112
SPIN-code: 7419-7690
Russian Federation, Khohlovsky lane 10, bldg. 5, Moscow 109028
Filipp V. Gorkavenko
The Center for Healthcare Quality Assessment and Control
Author for correspondence.
Email: fill-gor@yandex.ru
ORCID iD: 0000-0002-4586-2451
SPIN-code: 4274-4456
Russian Federation, Khohlovsky lane 10, bldg. 5, Moscow 109028
Evgeniya V. Nazarova
National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia
Email: evallergo@yandex.ru
ORCID iD: 0000-0003-0380-6205
SPIN-code: 4788-7407
MD, Cand. Sci. (Med.)
Russian Federation, Khohlovsky lane 10, bldg. 5, Moscow 109028Natalia I. Ilina
National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia
Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650
MD, Dr. Sci. (Med.), Professor
Russian Federation, Khohlovsky lane 10, bldg. 5, Moscow 109028Vitaly V. Omelyanovskiy
Russian Medical Academy of Continuous Professional Education; The Center for Healthcare Quality Assessment and Control; Federal state budgetary institution Scientific and research financial institute
Email: vvo@rosmedex.ru
ORCID iD: 0000-0003-1581-0703
SPIN-code: 1776-4270
MD, Dr. Sci. (Med.), Professor
Russian Federation, Khohlovsky lane 10, bldg. 5, Moscow 109028; Moscow; MoscowReferences
- The Russian Association of Allergologists and Clinical Immunologists, the National Medical Association of Otorhinolaryngologists, the Union of Pediatricians of Russia. Clinical recommendations «Allergic rhinitis». 2019. (In Russ). Available from: https://raaci.ru/dat/pdf/allergic_rhinitis-project.pdf. Accessed: 06.11.2021.
- Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. The Lancet. 2008;372(9643):1049–1057. doi: 10.1016/s0140-6736(08)61446-4
- Bousquet J, Schünemann HJ, Samolinski B, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–1062. doi: 10.1016/j.jaci.2012.07.053
- Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109(3):419–425. doi: 10.1067/mai.2002.121701
- Valero A, Pereira C, Loureiro C, et al. Interrelationship between skin sensitization, rhinitis, and asthma in patients with allergic rhinitis: a study of Spain and Portugal. J Inv Allergol Clin Immunol. 2009;19(3):167–172.
- Lombardi C, Passalacqua G, Gargioni S, et al. The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years. Respir Med. 2001;95(1):9–12. doi: 10.1053/rmed.2000.0945
- Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2017;73(1):165–177. doi: 10.1111/all.13213
- Schmitt J, Schwarz K, Stadler E, Wüstenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study. J Allergy Clin Immunol. 2015;136(6):1511–1516. doi: 10.1016/j.jaci.2015.07.038
- Devillier P, Molimard M, Ansolabehere X, et al. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: a retrospective database study in France. Allergy. 2019;74(7):1317–1326. doi: 10.1111/all.13705
- Wahn U, Bachert C, Heinrich J, et al. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2018;74(3):594–604. doi: 10.1111/all.13598
- Kurbacheva O, Pavlova K, Kozulina I. Allergen-specific immunotherapy: history, methods and new options. Medicinskii Sovet. 2013;(3-2):10–19. (In Russ).
- Kurbacheva O. Pharmacoeconomical analysis of allergenspecific immunotherapy. Problemy Standartizacii v Zdravoohranenii. 2007;(3):8–15. (In Russ).
- Ushakova D, Drinov G, Tikhomirova S, Slastushenskaya I. Clinical and economic effectiveness of allergyspecific immunotherapy in atopic bronchial asthma. Kremlevskaia Medicina. Klinicheskii vestnik. 2014;(2):25–29. (In Russ).
- Gushchin I, Kurbacheva O, Pavlova K. Economic rationality of allergen-specific immunotherapy. Pulmonologiia. 2005;(5):46–52. (In Russ). doi: 10.18093/0869-0189-2005-0-5-46-52
- Sobko E, Gordeeva N, Kraposhina A, et al. Clinical efficiency and the pharmacoeconomic analysis of allergen immunotherapy at patients with mild and moderate allergic bronchial asthma. Farmakoèkonomika. 2015;8(2):29–37. (In Russ). doi: 10.17749/2070-4909.2015.8.2.029-037
- Trifonova T, Popova L, Alemanova G, Bobkova E. Clinical and economic efficacy of sublingual allergenspecific immunotherapy in children with allergic rhinitis. Prakticheskaia Medicina. 2015;92(7):78–83. (In Russ).
- Poole CD, Bannister CA, Andreasen JN, et al. Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. Health Qual Life Outcomes. 2014;12(1):99. doi: 10.1186/1477-7525-12-99
- Sullivan PW, Kavati A, Ghushchyan VH, et al. Impact of allergies on health-related quality of life in patients with asthma. J Asthma. 2019;57(11):1263–1272. doi: 10.1080/02770903.2019.1645168
- Klifar. Commercial database. (In Russ). Available from: http://www.cliphar.ru/. Accessed: 06.11.2021.
- Russian Respiratory Society. Clinical recommendations “Bronchial asthma”. 2019. (In Russ). Available from: https://spulmo.ru/upload/kr_bronhastma_2019.pdf. Accessed: 06.11.2021.
- Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126(5):969–975. doi: 10.1016/j.jaci.2010.08.030
Supplementary files
